Home / Transcripts / American Vanguard Corporation (AVD) · November 10, 2025

American Vanguard Corporation (AVD) Earnings Call Transcript

November 10, 2025

New York Stock Exchange US Materials Chemicals earnings 38 min

Earnings Call Speaker Segments

Anthony Young executive
#1

Thanks, operator. Hello everyone, and thanks for joining American Vanguard's Third Quarter 2025 Earnings Review. Dak Kaye, our Chief Executive Officer, and David Johnson, our Chief Financial Officer, will present our prepared remarks. You can find a copy of today's release, plus supplemental slides, on our website. A replay of the webcast and a transcript from this event will also be posted to our website soon. Before we get into our comments, we want to remind everyone that today's press release and some of what we say on the call contain non-GAAP figures and forward-looking statements, and actual results could differ materially. Please see the cautionary language in our press release and slides, as well as the risk factors described in our SEC filings, all of which you can access on our website. I'll now hand the call over to our CEO, Dak Kaye.

Douglas Kaye executive
#2

Thanks, Anthony, and good morning, everyone — glad to have you on the call for our Q3 2025 earnings discussion. Eleven months have passed since I came aboard, and the mandate I received was to streamline, set priorities, and execute — and that's exactly what we're delivering. Our adjusted EBITDA climbed to $8.2 million this quarter, up from $1.8 million during the same period a year earlier, which works out to growth exceeding 350%. Seasonally speaking, Q3 tends to be our softest, while Q4 is our strongest, so we're looking for a solid wrap-up to the year. Even as the agricultural downturn continues, we're managing what's within our grasp — bringing down net trade working capital along with factory costs and operating expenses — all while setting up the company for significantly greater earnings once the agricultural market recovers. In a few moments, I'll walk you through how I see the agricultural market right now. So far, I'm happy with what we've achieved. Compared with the prior-year period, gross profit margins are up 300 basis points, and the operations team deserves much of the credit for that gain. Beyond that, we're refining how we manufacture — moving production out of L.A. and into Alabama, for instance, so we can get the most out of our production efficiencies. My expectation is that the bulk of the savings we've realized this quarter will remain with the company over the long haul. Steps have also been taken on the operating expense side; those costs are down roughly $6 million versus Q3 of 2024 and down $14 million across the 9-month period. Cuts have come from every part of the company. We're happy with our progress thus far, yet our attention stays fixed on expense discipline. Watching costs isn't a near-term project — it's a cultural shift here. Transformation still appears on our statement of operations for this quarter, but we're moving all of those activities in-house. We've got the talent to carry the transformation forward, and going ahead we'll call these efforts our business improvement initiative, since we're taking full ownership; we'd already brought the spend in that area down to $2 million from $8 million versus the third quarter of 2024, and we expect it to shrink to negligible levels in the quarters ahead. As part of simplifying the business, we're changing the name of our non-crop segment to the Specialty business. In our view, the non-crop label doesn't do justice to the technology, patents and innovation that this business is built on. The Specialty business may be smaller than our Crop business, but it carries critical mass, with key contracts for mosquito control and advanced technologies deployed in home pest control, ornamental and greenhouse applications, golf course, lawn and landscape care. Our present financials still call this business non-crop, though we expect the name change to show up in future financials. Even though our business improvement plan is already moving forward at a good pace, I believe we should take a moment to discuss the growth possibilities ahead of us. We haven’t spent much time on this during previous conference calls, but we are building a strong growth portfolio that could bring in $100 million of net sales over the medium term. This growth will come on top of our existing proven products, which will also increase through geographic expansion and by moving into new crops and sectors. That added volume should also support better factory utilization, which would further reduce the company’s overall cost structure. Now that SIMPAS is no longer a priority, the development team is concentrating on expanding our crop protection portfolio. Shifting to what we’re observing in the agricultural economy: we are in the middle of a strong U.S. harvest; however, trade tensions with China have cast a shadow over the industry, especially for U.S. soybean growers, where key trading channels are still uncertain. Although there are plenty of reasons for caution, there are also reasons for optimism, including lower channel inventories of our products, a declining interest rate environment, recent news suggesting China is resuming soybean purchases, and the chance of additional subsidies for growers. Given this uncertain backdrop, we remain confident in keeping our full year 2025 adjusted EBITDA target of $40 million to $44 million; we have reduced our 2025 net sales forecast to $520 million to $535 million to reflect various market conditions, mainly in Mexico, Central America and Australia; we will keep managing expenses tightly while making sure our manufacturing facilities operate as safely and efficiently as possible so we can maximize gross profit margin. We are confident that we are positioning the company for success in 2026 and beyond. I’ll now hand the call over to our CFO, David Johnson. David?

David Johnson executive
#3

Thanks, Dak. Morning, everyone. It's clear our business improvement program is delivering a favorable effect on our financial results, and we anticipate additional gains in the quarters ahead. For the third quarter of 2025, U.S. GAAP revenue came in at $119 million, versus $118 million during the comparable quarter of 2024 — that's a 1% rise. We ought to point out that revenue in the third quarter of 2024 took a hit from a nonrecurring item, and on an adjusted basis, the prior year figure would have been $130 million. Looking sequentially, our U.S. crop business turned in a solid performance, which made up for softer results in both Specialty and International. In U.S. crop, results were mixed: on one hand, the potato market stayed weak, which hurt our soil fumigant sales. On the other hand, we did well with herbicides, rising roughly 50%, and with granular soil insecticides, which were up around 5%. Broadly speaking, within U.S. crop, we think channel inventories remain low, and pricing pressure appears to have softened. In Specialty, we encountered some softness in our horticultural business, which was affected to a degree by the product liability matter. Though that business started the quarter slowly on a weekly basis, it gained momentum as the quarter went on, as customer confidence came back. In addition, our mosquito adulticide product had sluggish sales following a weak season with fewer storms, which left vector control districts in key states holding somewhat more inventory. International sales declined, a result of our strategic choices in Brazil to exit lower-margin business so our organization could concentrate on serving higher margin customers and products. In Australia, key regions experienced significant droughts, which brought sales down. Comparable weather patterns have hit certain areas of Central America, while the market in Mexico has yet to fully destock. On a U.S. GAAP basis, gross profit margin rose to 29% in the quarter, compared with a gross profit margin of 15% a year earlier. A moment ago, I referenced the nonrecurring item that weighed on sales at this point last year. Making those same adjustments to gross margin, we would have posted 26% in the third quarter of 2024; we still keep a tight grip on operating expenses. We lowered selling expense across both the 3- and 9-month periods, mainly because we put a more streamlined global organization structure in place. General and administrative expenses have also come down after the organization redesign, yet those cost savings are hidden by higher accruals for incentive compensation that reflect our year-to-date financial performance; we've made deeper cuts to research, product development and regulatory costs, concentrating on return on investment for product development projects and eliminating spending on the SIMPAS project. All told, our operating costs declined 11%, or $5 million, in the 3-month period, and $18 million, or 14%, year-to-date. Turning to the year's last quarter, as Dak said, we anticipate that the majority of the cost savings we've realized will persist, even though spending on product development tends to run higher in Q4. That said, R&D expenses are projected to come in under last year's level. Within the 9-month saving I just referred to, transformation activity spending came down by roughly $11 million. That decrease was planned, since we're now generating business improvements using internal resources. Countering that saving, during the third quarter of 2025 we took an expense tied to the product liability claims; regarding those claims, which involve the Specialty business, the company concluded it has enough information to book a liability for the anticipated cost of resolving them. We've established the required resources to handle the claims process, and we've begun claims assessment and payment processes; we anticipate that the expense booked this quarter will ultimately be fully reimbursed through a mix of funds from the at-fault counterparty and/or their insurers. We completed an assessment and concluded that moving ahead with settling customers' claims was in the company's best interest, despite the fact that right now we lack sufficient information to record the offsetting indemnification assets; now shifting to the balance sheet. Thanks to our enhanced SIOP process, we've been able to run with relatively lower inventory than was the case over the last 2 years. Our inventory sits at roughly $47 million below where it stood at this point a year ago. And as typically happens with our — for our annual business cycle, we anticipate a meaningful inventory drawdown in the year's fourth quarter. Our net trade working capital came in about $24 million under this point last year. We maintain a strong focus on these balance sheet items as we aim to minimize drawing on our revolving credit line; we've lowered our net debt versus the same period a year ago by about $2 million, to $165 million. Although our net debt fell only slightly, we accepted less early pay during the quarter than at this point last year. Though customer interest ran high, we took the strategic step of pursuing far less early pay in the third quarter of 2025 than we did in 2024. As always, we'll be engaging with customers on early pay options during this year's fourth quarter. Since our previous conference call, we announced reaching an agreement with our senior lenders to push out the maturity of our credit facility to December 31, 2026. As we keep enhancing the business, we'll keep working with both our existing lenders and prospective new lenders to restructure our debt; we believe that as we keep delivering, lenders ought to be attracted by our stronger profitability and cash flow profile. We’re eager to give the investment community an update on that initiative when the right moment comes. During the previous call, we mentioned that we anticipate CapEx of $5 million to $6 million in 2025, along with our expectation for the full year of $40 million to $44 million in adjusted EBITDA. So, we expect to produce fairly appealing cash flow in Q4 of the year. Nearly all of that free cash flow will go toward paying down debt. With that, I’ll hand the call back over to our CEO. Dak?

Douglas Kaye executive
#4

Thanks, David. Before we take questions on the call, I want to express appreciation to the team for putting in place the changes required to make this business better. The effort you're putting in is generating real, measurable outcomes. As the market recovers gradually, our attention will stay on what's within our control: boosting manufacturing efficiency, watching net trade working capital closely, and holding operating expenses down, all while pursuing long-term growth opportunities. This company has consistently shown resilience, with products that are proven and effective and supported by the finest technical team in the industry. It's also a company capable of generating even stronger cash flow now that we operate as a globally integrated organization. American Vanguard has a bright future, with a strong product pipeline, an improved cost structure, and a dedicated team, and we will stay on course to be the trusted provider of proven agriculture and environmental solutions; with that, I'll turn the call over to questions. Operator?

Mike Harrison analyst
#5

To kick things off, I was hoping we might spend a moment discussing a few of the patterns you're noticing throughout the various segments of your company. Perhaps we begin with how well U.S. crop is doing — from what I gather, the herbicides category delivered a really solid result for you. Could you explain what was behind that, and perhaps share how you view the momentum heading into Q4 and the early stretch of next year?

Douglas Kaye executive
#6

Absolutely. U.S. crop did quite — turned in a really strong Q3. Like you said, the herbicides, Impact and Envoke, delivered really strongly on a year-over-year basis, and Aztec did as well during the quarter. What we're observing is demand in the U.S. crop business that's closer to normal. Because of that, we don't need to provide the same level of incentives that we have — that we did back in Q1. There's far more optimism throughout the — within the channel among distributors. A cloud does still linger, with growers out in the market regarding tariffs and how they affect soybeans, mainly; but overall, corn acres, we saw them rise this year, and projections show them rising again next year, which is a positive sign for our portfolio in the U.S.

Mike Harrison analyst
#7

Okay, so about the non-crop segment — or Specialty, as you refer to it — it seems like that product liability matter may have held back a portion of that operation. Is this largely a one-off thing, meaning Specialty returns to expansion by the time we reach Q4? Or will that product liability problem keep weighing things down across several additional months or quarters?

Douglas Kaye executive
#8

Yeah, fair question, Mike. When it comes to accounting, we have already recorded the effect of that possible claim. The offset is still something we're working through — that mitigation piece — and we hold full confidence that reimbursement for our claim will come. We bear absolutely no fault, and the counterparty is related. Still, it acted as a drag during the initial portion of Q3 within Specialty. Once we began processing those claims and getting word out to customers more quickly, from the middle to the end, things appear to be moving much more smoothly now. The market has actually responded very well; customers have been quite happy that, given the circumstances, we began processing these claims. Therefore, my view is that this won't be a long-term effect. My expectation is that you'll see Specialty grow in Q4 as well as in Q1.

Mike Harrison analyst
#9

All right, I'm glad to hear that. Then, David, could you talk a little about how much free cash flow you expect to generate this year? I believe your wording was "reasonably attractive" — can you put any numbers behind that? It looks like working capital is improving nicely, and that should improve further in Q4.

David Johnson executive
#10

Yeah. I mean, cash coming in during Q3 was strong relative to what we did in the first 2 quarters, so we felt good about that. It was somewhat smaller than the same period a year ago. Yet, to repeat what I mentioned during my formal comments, when we went after those advance payments, the total came in below the prior year's figure, though it exceeded our own target. That represented a favorable development. How much cash we bring in during the last quarter will be shaped somewhat by those advance payments, yet things appear quite favorable right now. Consequently, I anticipate receipts comparable to the prior year, which proved to be a very robust period.

Mike Harrison analyst
#11

Okay, and the final thing I have concerns the transformation effort. It sounds as though handing that over to the in-house group is a genuinely significant milestone, so I was hoping...

Douglas Kaye executive
#12

Has Mike dropped off?

Mike Harrison analyst
#13

My apologies — is my voice coming through now?

David Johnson executive
#14

For a second there, we couldn't hear you.

Douglas Kaye executive
#15

If you could repeat the question, Mike. Appreciate it.

Mike Harrison analyst
#16

Yeah. Moving — shifting the transformation work over to the in-house group seems like a big deal. Could you explain how significant that is? And perhaps also share a bit about the way we ought to view possible cost reductions and additional steps as we head into the coming year?

Douglas Kaye executive
#17

Thanks, Mike. Handing the transformation effort to our business improvement initiative is a key change. The main reason is to refine it and run it with our own people and build ownership of the plan moving forward. As I've mentioned several times on investor calls, there's substantial upside, and I think Kearney put together a strong collection of initiatives that gave us a blueprint to carry ahead. That said, in my view the plan was truly focused on easy wins, and plenty of other fruit remains on the tree for us to pick, particularly around manufacturing efficiencies, and once the SIOP process becomes more formalized, we'll realize gains there across the P&L and EBITDA.

Wayne Pinsent analyst
#18

Dak, congratulations on the solid improvement we saw during the quarter. I just wanted to ask — someone at a rival company mentioned on their recent call that generic pressure has been heating up in the market. I'd love to hear what you think about that, and whether it's having any effect on you folks? I realize you've pointed out that pricing is beginning to level off, but is there anything else you can share?

Douglas Kaye executive
#19

Sure. I won't comment specifically on what's happening with that competitor. As far as we're concerned, though, there's a single product of ours that faced competition across the past 2 years. To be frank, we believe we're sitting in a really strong position this year, and volumes have risen thanks to a range of market conditions, I'd say. On top of that, there's an advantage we enjoy from being a domestic U.S. supplier and manufacturer, and particularly for the product I just mentioned, Folex, that gives us an edge. We also expect higher volumes in 2026 with Folex, and we're making plans for that; so generic competition is simply always going to exist in this marketplace. What I'd say is that it's always essential to stay aware and anticipate those kinds of situations, and to be sure you're preparing appropriately.

Wayne Pinsent analyst
#20

All right. So nothing notably different from what you've been observing?

Douglas Kaye executive
#21

That's right.

Wayne Pinsent analyst
#22

Also, Corteva said they're breaking their seed and crop operations apart. For AVD going forward, are there any upsides or downsides there?

Douglas Kaye executive
#23

My sense is there's going to be some — I mean, this covers a lot. Given what the other big players intend to do, plus what Bayer might potentially do, I believe the marketplace will see some consolidation; so ultimately, over the coming 12 to 18 months, there's going to be some consolidation in the marketplace. And when consolidation happens, we see a big chance to return to what we did 10 years ago, which was purchasing a portfolio of products from the basics as they go through these consolidation period; so over the next 12 to 18 months, I think there will be a genuine chance to grow the portfolio via acquisitions. That, in my view, is the most positive part of it.

Wayne Pinsent analyst
#24

Moving on — I realize a 2026 forecast isn't something you'll provide, yet I'd still like your perspective regarding volume and pricing patterns. You said pricing has gotten better and appears to be leveling off. So tell us what you're observing, and assuming the crop protection market levels off and goes back to a more typical low single-digit increase, what kind of results do you believe AVD could deliver in that setting, given the past few years have been down?

Douglas Kaye executive
#25

My belief is our results will be strong. What I mean is — we built this company to deliver very strong results in 2026. You have the transformation plan from 2024, the team being reorganized, global best practices being put in place during 2025, which sets things up for what I view as a very positive 2026 outlook. And in my view, the team sits in a great position. The organization sits in a great position; we hold a clear vision of our identity and our destination. The pipeline, I believe, keeps expanding; it won't arrive in 2026, though it will arrive in '27, '28, '29; therefore we will reach that point; and given how things stand now with the market having leveled off and channel inventories reduced, we ought to clearly witness rising volumes in 2026.

Wayne Pinsent analyst
#26

All right. Fantastic. Then the final one from my side, and you already mentioned this a moment ago. That $100 million in net sales across the medium term coming out of the pipeline — can you share anything further, and also how you'd expect the timing or cadence of that to unfold?

Douglas Kaye executive
#27

Yeah. Excellent question, and I appreciate you bringing it up, since it's a topic that genuinely excites me. When I initially arrived at American Vanguard, I felt somewhat let down by the product pipeline that existed here. And I believe that happened for several reasons — the SIMPAS technology absorbed so much of the attention that new products, relatively speaking, weren't getting focus. That said, as we moved into this year and began organizing and analyzing, there were some truly strong products sitting in that pipeline, which we advanced and cleaned — cleared — moved through the stage gate process in order to formalize things and reach that $100 million figure we're discussing. There's a genuinely strong product spread fairly broadly across U.S. crops, international markets, and Specialty. As I mentioned, a gap exists here. We won't see those new product sales come to fruition until materially — until it starts in '28. Simply because bringing a new product to market takes 2 years in most cases, 2 to 3 years; so what I think we achieved over this past year is the capability to bring the new product pipeline into focus and assign accountability to the timeline for getting these new products to market. And I'm more — I'm truly optimistic about it now that we've put it on paper, examined it, and validated them. So it's quite exciting.

Charlie Rose analyst
#28

I'd like to walk through a few figures related to the free cash flow matters, simply to confirm I've recorded them correctly, more or less. It appears that should you produce somewhere in the range of $40 million to $44 million of EBITDA, I subtract, say, $5 million or $6 million of CapEx, perhaps there's $1 million or $2 million of cash taxes at the most. My sense is cash taxes aren't significant; and after that interest expense amounts to $20 million. And then possibly working capital provides a source of funds, my assumption being working capital might contribute $5 million or $6 million as a source of funds across the full year. You end up with free cash flow of roughly $20 million. Is that more or less how one should view it?

Douglas Kaye executive
#29

That's precisely how I would write it out. Regarding interest, we ought to come in slightly below $20 million. Still, yes, that's a solid estimate, Charlie.

Charlie Rose analyst
#30

All right. So taking that model out a bit more, at this point, with $165 million of EBITDA — my mistake, I meant $165 million of net debt and $40 million to $44 million of EBITDA — your leverage ratio sits at 4x. So come next year, say you can push those figures up to somewhere around $50 million, and you can bring the debt down by an additional $20 million, you ought to be able to knock off 1 turn of leverage. Is that roughly the target you're aiming at, Dak?

Douglas Kaye executive
#31

Getting that figure below 3 is definitely the main objective we're pursuing there.

Charlie Rose analyst
#32

So when you approach a refinancing situation, that's basically the approach you'd take, correct?

Douglas Kaye executive
#33

Yes, absolutely. During Q2 and Q3, our results have demonstrated favorable momentum. And at present, we're right in the middle of the mix for the refinancing initiative — right in the thick of it.

Charlie Rose analyst
#34

So the final thing I'd like to address — this came up before, regarding Corteva. Clearly, businesses are being positioned to capitalize on consolidation; and then there's this matter with FMC and what we might term their difficulties. Could you shed some light on that too, Dak, if you're willing, just to tell us whether there's something more seriously wrong there? Or whether it's less of a problem than we — than the market seems to be implying. I'd really like to hear your perspective on all of this, since we're now witnessing a distinction among the various challenges facing the ag sector.

Douglas Kaye executive
#35

Yeah. I'll be reluctant to comment on that particular competitor, Charlie. I do have certain views about it. But I'd truly prefer not to get into that, if that works for you.

Charlie Rose analyst
#36

All right, that makes sense. Given how heavily leveraged this business is, plus what looks like growing difficulties around their products and their there — the situation might be far worse than any of us assume; I simply hoped to hear your perspective, though I realize you won't be offering any remarks. Fine. In any case, best wishes as you keep pushing this company ahead, and I'm eager to see what next quarter brings too.

Dmitry Silversteyn analyst
#37

Nice work on a strong quarter. I'd like to dig a bit deeper regarding the improvement in your gross margin — 300 basis points of adjusted gross margin year-over-year, considering everything happening across the industry, is quite remarkable. So I wondered whether this stemmed largely from the manufacturing gains you've achieved during the last year. Did pricing or mix play any role? What were the main buckets behind achieving that 3-point improvement on a year-over-year basis?

Douglas Kaye executive
#38

Yes. Dmitry, excellent question, and I appreciate you raising it. My view is that multiple factors are at play, rather than any single one. Sales are beginning to move into the marketplace more smoothly, particularly within the U.S., and with fewer incentives as well. The SIOP process, as I see it, now permits inventory replacement cost to pass through the P&L after we've burned through much of that older inventory, and that's boosting margin; beyond that, I'd point to the manufacturing efficiencies we — this reflects both our emphasis on manufacturing operations and the alignment and dialogue among demand planning, production planning and procurement, which together are driving margin expansion too. So my sense is that several elements combine here; and above all, it's the outstanding teamwork happening at American Vanguard.

Dmitry Silversteyn analyst
#39

So it sounds like the level of promotional activity you needed this quarter was lower than what you had this time last year. That means pricing or mix likely got a bit better, and on top of that, your internal improvements on the manufacturing cost side helped too. As you look ahead toward the end of the year and into early 2026, is there anything — any worries about raw materials, anything causing you trouble or making you think your costs will rise more quickly than inflation, so to speak.

Douglas Kaye executive
#40

No, Dmitry. I mean, really not. I mean, we've analyzed the tariff impact heavily. A portion exists, yes—though frankly, reduced cost of goods sold and cheaper raw materials are absorbing the bulk of that tariff hit, so the effect has largely been softened. Only a week ago the procurement group and I were reviewing a particular raw material, and its price is trending down favorably. Consequently, nothing within our COGS is currently rising, as far as I can tell.

Dmitry Silversteyn analyst
#41

Great. Now for my final question, let's talk about the overall sentiment out there in the market. You mentioned that inventories are reaching a more suitable position within the supply chain and internally for your company. Since the outlook seems quite positive, and you noted that acreage in North America will probably rise once more next year, do you anticipate that your season across Q4 and Q1 will unfold more typically, with end-market demand showing up in your results rather than being driven mostly by distributors working down stock?

Douglas Kaye executive
#42

Yeah. Yeah. So, from my perspective — well, not just my perspective, but based on what the data from our systems tells us, the third-party information we receive regarding channel inventories — our products sit at very low levels, and they're even lower than they were a year ago. That gives us confidence that inventories have come down, meaning normal purchasing patterns are returning. As for what normal purchasing looks like, we don't think it will involve stockpiling; however, across a full year, what gets purchased and what gets sold ought to match up. So at this moment, absent some unforeseen black swan occurrence, we don't expect they'll go back to stockpiling the way they did just before COVID, simply because there's ample supply in the market and buyers are now aware of that.

Operator operator
#43

Thanks. That wraps up both the Q&A portion and the entire call, everyone. Today's session is now finished, so feel free to hang up whenever you're ready — and we appreciate you joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Vanguard Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to American Vanguard Corporation earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.